Anti-CD30 antibody

Overview
- CD30, a single chain glycoprotein, is synthesized as a 90kDa precursor which is processed in the Golgi complex into a membrane‐bound phosphorylated mature 105/120kDa glycoprotein. The CD30/Ki‐1 antigen is expressed by mononuclear Hodgkin and multinucleated Reed‐Sternberg cells in Hodgkin’s disease, by the tumor cells of a majority of anaplastic large cell lymphomas, and by a varying proportion of activated T and B cells. Ber‐H2 distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki‐1 positive lymphomas lack the leukocyte common antigen (CD45).
  
  Please contact us at for specific academic pricing.
  
  More Details
  
  ST John's Labs
Properties
- Host
  
  mouse
  
  Antibody Type
  
  monoclonal
  
  Isotype
  
  IgG1 kappa
  
  Reactivity
  
  human
  
  Clone
  
  Ber‐H2
  
  Immunogen
  
  Co cell line established from a patient with Hodgkin's disease of T‐cell lineage
  
  Conjugate
  
  Unconjugated
  
  Formulation
  
  Purified antibody diluted in Tris‐HCI buffer containing stabilizing protein and <0.1% sodium azide.
  
  Storage
  
  Store at 2-8°C for up to 1 year
  
  Regulatory Status
  
  RUO
  
  Antigen
  
  Tumor Necrosis Factor Receptor Superfamily Member 8; Cd30l Receptor; Ki-1 Antigen; Lymphocyte Activation Antigen Cd30; Cd Antigen Cd30 (Gene ID:943; UniProt:P28908)
  
  * For research use only